abt-700 + folfiri + cetuximab

**ABT-700 + FOLFIRI + cetuximab** is a combination regimen under investigation for the treatment of advanced/metastatic solid tumors, particularly colorectal cancer. - **ABT-700** is a humanized monoclonal antibody targeting the c-Met (MET, hepatocyte growth factor receptor), inhibiting ligand (HGF) binding and downstream signaling[1][3][5][7]. This can induce apoptosis and inhibit proliferation in MET-amplified or c-Met-overexpressing tumors. - **FOLFIRI** is a standard chemotherapy regimen comprising folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. It acts by inhibiting DNA synthesis and topoisomerase I, leading to cell death[2][4][6]. - **Cetuximab** is an anti-EGFR monoclonal antibody which blocks epidermal growth factor receptor signaling, thereby impeding cell proliferation[4]. This combination exploits complementary antitumor mechanisms: targeted c-Met blockade, cytotoxic chemotherapy, and EGFR inhibition. Primary indications are colorectal cancer and other advanced solid tumors with c-Met amplification or EGFR expression. ABT-700 was developed by AbbVie[1][3][5][7].

Other names

abt-700 + folfiri + cetuximab